Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 36

Sort by

Sort Order Select

Journal Articles

Lisocabtagene maraleucel (liso-cel) versus standard of care (SOC) for second-line relapsed or refractory large B-cell lymphoma (LBCL): First Results from long-term follow-up of TRANSFORM

Manali Kamdar, Scott Solomon, Jon Arnason, Patrick Johnston, Bertram Glass, Veronika Bachanova, Sami Ibrahimi, Stephan Mielke, Pim Mutsaers, Francisco Hernandez-Ilizaliturri, Koji Izutsu, Franck Morschhauser, Matthew Lunning, Vincent Ribrag, Yi Lin, Rashmi Bhatnagar, Sandrine Montheard, Jeremy Abramson

Blood (2025) 146 (Supplement 1): 3710.

https://doi.org/10.1182/blood-2025-3710

Published: 2025

Journal Articles

Firicabtagene autoleucel (firi-cel), a CD22-directed CAR T-cell therapy, for patients with relapsed/refractory large B-cell lymphoma: Results from the phase 2 study (FIRCE-1 Trial)

Blood (2025) 146 (Supplement 1): 667.

https://doi.org/10.1182/blood-2025-667

Published: 2025

Journal Articles

Phase I/II study of acalabrutinib, venetoclax, and obinutuzumab in patients with relapsed/refractory and previously untreated Mantle Cell Lymphoma (MAVO)

Blood (2025) 146 (Supplement 1): 664.

https://doi.org/10.1182/blood-2025-664

Published: 2025

Journal Articles

High complete response rates and minimal residual disease (MRD) negativity, with durable responses, in high-risk mantle cell lymphoma (MCL) with GLPG5101, a fresh, early memory-enriched CAR T-cell therapy with a 7-day vein-to-vein time: Results from the ATALANTA-1 MCL cohort

Blood (2025) 146 (Supplement 1): 662.

https://doi.org/10.1182/blood-2025-662

Published: 2025

Journal Articles

High complete response rates, low dropout rate, and low-grade toxicities in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) receiving GLPG5101, a fresh, early memory-enriched CAR T-cell therapy with a 7-day vein-to-vein time: Results from the ATALANTA-1 DLBCL cohort

Blood (2025) 146 (Supplement 1): 5940.

https://doi.org/10.1182/blood-2025-5940

Published: 2025

Journal Articles

Axicabtagene ciloleucel versus tisagenlecleucel in relapsed or refractory diffuse large B-cell lymphoma

Jia Yi Tan, Hermon Wong, Aravinthan Vignarajah, Daniel Ezekwudo, Jon Arnason, Talal Hilal

Blood (2025) 146 (Supplement 1): 6282.

https://doi.org/10.1182/blood-2025-6282

Published: 2025

Journal Articles

Phased variant circulating tumor DNA (ctDNA) tracking provides limited additional power in predicting progressive disease compared with duplex variant tracking in patients with Relapsed/Refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL) treated with odronextamab

Jon Arnason, Won Seog Kim, David Tucker, Sabarish Ayyappan, Wei-Yi Cheng, Weiwei Tao, Namita Gupta, Hesham Mohamed, Aafia Chaudhry, Jurriaan Brouwer-Visser

Blood (2025) 146 (Supplement 1): 5309.

https://doi.org/10.1182/blood-2025-5309

Published: 2025

Journal Articles

Two-year follow-up of lisocabtagene maraleucel in relapsed or refractory large B-cell lymphoma in TRANSCEND NHL 001

Jeremy S. Abramson, M. Lia Palomba, Leo I. Gordon, Matthew Lunning, Michael Wang, Jon Arnason, Enkhtsetseg Purev, David G. Maloney, Charalambos Andreadis, Alison Sehgal, Scott R. Solomon, Nilanjan Ghosh, Christine Dehner, Yeonhee Kim, Ken Ogasawara, Ana Kostic, Tanya Siddiqi

Blood (2024) 143 (5): 404–416.

https://doi.org/10.1182/blood.2023020854

Published: 2024

Includes: Supplemental data

Journal Articles

Phase 2 clinical trial evaluating abatacept in patients with steroid-refractory chronic graft-versus-host disease

Blood (2023) 141 (24): 2932–2943.

https://doi.org/10.1182/blood.2022019107

Published: 2023

Includes: Supplemental data

Journal Articles

Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study

Jeremy S. Abramson, Scott R. Solomon, Jon Arnason, Patrick B. Johnston, Bertram Glass, Veronika Bachanova, Sami Ibrahimi, Stephan Mielke, Pim Mutsaers, Francisco Hernandez-Ilizaliturri, Koji Izutsu, Franck Morschhauser, Matthew Lunning, Alessandro Crotta, Sandrine Montheard, Alessandro Previtali, Ken Ogasawara, Manali Kamdar

Blood (2023) 141 (14): 1675–1684.

https://doi.org/10.1182/blood.2022018730

Published: 2023

Includes: Supplemental data

Journal Articles

Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL

Tanya Siddiqi, Jacob D. Soumerai, Kathleen A. Dorritie, Deborah M. Stephens, Peter A. Riedell, Jon Arnason, Thomas J. Kipps, Heidi H. Gillenwater, Lucy Gong, Lin Yang, Ken Ogasawara, Jerill Thorpe, William G. Wierda

Blood (2022) 139 (12): 1794–1806.

https://doi.org/10.1182/blood.2021011895

Published: 2022

Includes: Supplemental data

Journal Articles

Contribution of clonal hematopoiesis to adult-onset hemophagocytic lymphohistiocytosis

Blood (2020) 136 (26): 3051–3055.

https://doi.org/10.1182/blood.2020008206

Published: 2020

Includes: Supplemental data

Journal Articles

Phase 1 clinical trial evaluating abatacept in patients with steroid-refractory chronic graft-versus-host disease

Blood (2018) 131 (25): 2836–2845.

https://doi.org/10.1182/blood-2017-05-780239

Published: 2018

Includes: Supplemental data

Journal Articles

MUC1-mediated induction of myeloid-derived suppressor cells in patients with acute myeloid leukemia

Blood (2017) 129 (13): 1791–1801.

https://doi.org/10.1182/blood-2016-07-730614

Published: 2017

Includes: Supplemental data

Journal Articles

A Novel Dendritic Cell-Derived Vaccine in Multiple Myeloma

Rebecca Karp Leaf, MD, Dina Stroopinsky, PhD, Athalia Rachel Pyzer, MD, Ada M. Kruisbeek, PhD, Sandra Van Wetering, PhD, Abigail J. Washington, BA, Leandra Cole, BA, Myrna R. Nahas, MD, Salvia Jain, MD, Arie Apel, MD, Jon Arnason, MD, Ayad Hamdan, MD, Jacalyn Rosenblatt, MD, David E. Avigan, MD

Blood (2016) 128 (22): 4484.

https://doi.org/10.1182/blood.V128.22.4484.4484

Published: 2016

Journal Articles

TGR-1202 in Combination with Ibrutinib in Patients with Relapsed or Refractory CLL or MCL: Preliminary Results of a Multicenter Phase I/Ib Study

Matthew S. Davids, Haesook T. Kim, PhD, Alyssa Nicotra, BA, Alexandra Savell, BS, Karen Francoeur, RN, Jeffrey Hellman, PA-C, Hari P. Miskin, MS, Peter Sportelli, Asad Bashey, MD PhD, Laura Stampleman, MD, Jens Rueter, MD, Adam Boruchov, MD, Jon Arnason, MD, Caron A. Jacobson, MD, David C. Fisher, MD, Jennifer R. Brown

Blood (2016) 128 (22): 641.

https://doi.org/10.1182/blood.V128.22.641.641

Published: 2016

Journal Articles

Acute Myeloid Leukemia Cells Export c-Myc in Extracellular Vesicles Driving a Proliferation of Immune-Suppressive Myeloid-Derived Suppressor Cells

Athalia Rachel Pyzer, MD, Dina Stroopinsky, PhD, Hasan Rajabi, PhD, Abigail J. Washington, BA, Leandra Cole, BA, Salvia Jain, MD, Ashujit Tagde, PhD BPharm, Arie Apel, MD, Malgorzata McMasters, MD, James D. Levine, MD, Robin Joyce, MD, Jon Arnason, MD, Poorvi Somaiya, Rebecca Karp Leaf, MD, Myrna R. Nahas, MD, Donald Küfe, MD, Jacalyn Rosenblatt, MD, David E. Avigan, MD

Blood (2016) 128 (22): 703.

https://doi.org/10.1182/blood.V128.22.703.703

Published: 2016

Journal Articles

Phase I Clinical Trial Evaluating Abatacept in Patient with Steroid-Refractory Chronic Graft Versus Host Disease

Blood (2016) 128 (22): 387.

https://doi.org/10.1182/blood.V128.22.387.387

Published: 2016

Journal Articles

Transcend NHL 001: Immunotherapy with the CD19-Directed CAR T-Cell Product JCAR017 Results in High Complete Response Rates in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Jeremy S. Abramson, MD, Lia Palomba, MD, Leo I Gordon, MD, Matthew Lunning, DO, Jon Arnason, MD, Andres Forero-Torres, MD, Tina M. Albertson, MD PhD, Victoria Shaw Exton, Claire Sutherland, PhD, Benhuai Xie, PhD, Susan Snodgrass, MD, Tanya Siddiqi, MD

Blood (2016) 128 (22): 4192.

https://doi.org/10.1182/blood.V128.22.4192.4192

Published: 2016

Journal Articles

MUC1-C Inhibition Leads to Decrease in PD-L1 Levels Via up-Regulation of Micro RNAs

Blood (2016) 128 (22): 2871.

https://doi.org/10.1182/blood.V128.22.2871.2871

Published: 2016

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Lisocabtagene maraleucel (liso-cel) versus standard of care (SOC) for second-line relapsed or refractory large B-cell lymphoma (LBCL): First Results from long-term follow-up of TRANSFORM

Firicabtagene autoleucel (firi-cel), a CD22-directed CAR T-cell therapy, for patients with relapsed/refractory large B-cell lymphoma: Results from the phase 2 study (FIRCE-1 Trial)

Phase I/II study of acalabrutinib, venetoclax, and obinutuzumab in patients with relapsed/refractory and previously untreated Mantle Cell Lymphoma (MAVO)

High complete response rates and minimal residual disease (MRD) negativity, with durable responses, in high-risk mantle cell lymphoma (MCL) with GLPG5101, a fresh, early memory-enriched CAR T-cell therapy with a 7-day vein-to-vein time: Results from the ATALANTA-1 MCL cohort

High complete response rates, low dropout rate, and low-grade toxicities in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) receiving GLPG5101, a fresh, early memory-enriched CAR T-cell therapy with a 7-day vein-to-vein time: Results from the ATALANTA-1 DLBCL cohort

Axicabtagene ciloleucel versus tisagenlecleucel in relapsed or refractory diffuse large B-cell lymphoma

Phased variant circulating tumor DNA (ctDNA) tracking provides limited additional power in predicting progressive disease compared with duplex variant tracking in patients with Relapsed/Refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL) treated with odronextamab

Two-year follow-up of lisocabtagene maraleucel in relapsed or refractory large B-cell lymphoma in TRANSCEND NHL 001

Phase 2 clinical trial evaluating abatacept in patients with steroid-refractory chronic graft-versus-host disease

Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study

Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL

Contribution of clonal hematopoiesis to adult-onset hemophagocytic lymphohistiocytosis

Phase 1 clinical trial evaluating abatacept in patients with steroid-refractory chronic graft-versus-host disease

MUC1-mediated induction of myeloid-derived suppressor cells in patients with acute myeloid leukemia

A Novel Dendritic Cell-Derived Vaccine in Multiple Myeloma

TGR-1202 in Combination with Ibrutinib in Patients with Relapsed or Refractory CLL or MCL: Preliminary Results of a Multicenter Phase I/Ib Study

Acute Myeloid Leukemia Cells Export c-Myc in Extracellular Vesicles Driving a Proliferation of Immune-Suppressive Myeloid-Derived Suppressor Cells

Phase I Clinical Trial Evaluating Abatacept in Patient with Steroid-Refractory Chronic Graft Versus Host Disease

Transcend NHL 001: Immunotherapy with the CD19-Directed CAR T-Cell Product JCAR017 Results in High Complete Response Rates in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

MUC1-C Inhibition Leads to Decrease in PD-L1 Levels Via up-Regulation of Micro RNAs

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only